Browsing Tag
HMBD-002
1 post
Percheron Therapeutics (ASX: PER) licenses HMBD-002 cancer drug from Hummingbird in oncology pivot
Percheron Therapeutics acquires global rights to phase II-ready cancer drug HMBD-002 from Hummingbird Bioscience. Learn what this means for investors.